Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
Factor XIII A Double Nickase Plasmid (h): sc-402690-NIC
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- Factor XIII A Double Nickase Plasmid (h) consists of a pair of plasmids each encoding a D10A mutated Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed to knockout gene expression with greater specificity than its CRISPR/Cas9 KO counterpart
- Paired gRNA sequences are offset by approximately 20 bp to allow for specific Cas9-mediated double nicking of the genomic DNA, which mimics a DSB
- One plasmid in the pair contains a puromycin-resistance gene for selection; the other plasmid in the pair contains a GFP marker to visually confirm transfection
- Factor XIII A Double Nickase Plasmid (h) and Factor XIII A Double Nickase Plasmid (h2) encode distinct paired gRNA designs targeting F13A1. One or both designs may be available
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: Factor XIII A Antibody (A-4): sc-271122
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Factor XIII A Double Nickase Plasmid (h) | sc-402690-NIC | 20 µg | $410.00 | |||
Factor XIII A Double Nickase Plasmid (h2) | sc-402690-NIC-2 | 20 µg | $410.00 |
F13A1 encodes the A subunit of coagulation factor XIII, a transglutaminase that catalyzes covalent crosslinking of fibrin to stabilize clots and regulate fibrinolysis after thrombin activation. Factor XIII A participates in the terminal phase of the coagulation cascade and contributes to extracellular matrix remodeling and wound repair by crosslinking fibrin and other protein substrates. Disruption or altered activity of F13A1 is associated with abnormal clot stability and bleeding phenotypes, and dysregulated crosslinking has been studied in thrombotic and inflammatory contexts. As a myeloid-enriched cytosolic enzyme that becomes functionally integrated into fibrin networks, Factor XIII A is also relevant to studies of platelet–leukocyte interactions and tissue repair mechanisms.
Factor XIII A Double Nickase Plasmid (h) consists of a matched pair of plasmids engineered for high-specificity editing of the F13A1 locus in human cell lines. Each plasmid expresses a Cas9 D10A nickase and a distinct sgRNA targeting opposite DNA strands within F13A1. When directed to adjacent sites on opposite DNA strands, the two nickases generate offset single-strand nicks that together produce a staggered double-strand break, requiring coordinated on-target activity from both guides. The resulting DNA break is resolved by endogenous cellular repair pathways, most commonly through non-homologous end joining (NHEJ), leading to insertions or deletions that disrupt F13A1 function. By requiring dual sgRNA engagement at the target locus, the double nicking approach enhances editing specificity and provides a complementary CRISPR strategy for applications where additional control over targeting precision is desired.
To support efficient identification of edited cells, one plasmid encodes GFP for fluorescent visualization of transfected populations, while the companion plasmid carries a puromycin resistance gene for antibiotic selection. Together, these features support efficient enrichment of co-transfected populations and simplify the validation of F13A1-disrupted clones.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.